Show simple item record

dc.contributor.authorPettersen, Trond Røed
dc.contributor.authorSchjøtt, Jan Didrik
dc.contributor.authorAllore, Heather
dc.contributor.authorBendz, Bjørn
dc.contributor.authorBorregaard, Britt
dc.contributor.authorFridlund, Bengt
dc.contributor.authorHadjistavropoulos, Heather
dc.contributor.authorLarsen, Alf Inge
dc.contributor.authorNordrehaug, Jan Erik
dc.contributor.authorRasmussen, Trine Bernholdt
dc.contributor.authorRotevatn, Svein
dc.contributor.authorValaker, Irene
dc.contributor.authorWentzel-Larsen, Tore
dc.contributor.authorNorekvål, Tone Merete
dc.date.accessioned2025-02-12T09:58:10Z
dc.date.available2025-02-12T09:58:10Z
dc.date.created2024-01-18T15:44:18Z
dc.date.issued2024
dc.identifier.issn1443-9506
dc.identifier.urihttps://hdl.handle.net/11250/3177669
dc.description.abstractAim There are discrepancies between the information patients desire about adverse drug reactions (ADRs) and the information they receive from healthcare providers; this is an impediment to shared decision-making. This study aimed to establish whether patients received information about ADRs resulting from prescribed pharmacotherapy, before hospital discharge, after percutaneous coronary intervention (PCI) and to determine whether receiving information about ADRs was associated with incidence of self-reported ADRs or concerns related to prescribed pharmacotherapy. Methods CONCARDPCI, a prospective multicentre cohort study including 3,417 consecutive patients after PCI, was conducted at seven high-volume referral PCI centres in two Nordic countries. Clinical data were collected from patients’ medical records and national quality registries. Patient-reported outcome measures were registered 2 months (T1), 6 months (T2), and 12 months (T3) after discharge. Covariate-adjusted logistic regression yielded adjusted odds ratios (aORs) with 95% confidence intervals (CIs). Results At discharge, 38% of participants had been informed about potential ADRs. For these patients, the incidence of self-reported ADRs was significantly lower at T1 (aOR 0.61, 95% CI 0.50–0.74; p<0.001), T2 (aOR 0.60, 95% CI 0.49–0.74; p<0.001), and T3 (aOR 0.57, 95% CI 0.46–0.71; p<0.001). Those who were not informed reported higher levels of concern about prescribed pharmacotherapy at all measuring points (p<0.001 for all comparisons). Those living alone (aOR 0.73, 95% CI 0.57–0.92; p=0.008), who were female (aOR 0.57, 95% CI 0.44–0.72; p<0.001), and with three or more versus no comorbidities (aOR 0.61, 95% CI 0.44–0.84; p=0.002) were less likely to receive information. Conclusion A substantial proportion of patients were not informed about potential ADRs from prescribed pharmacotherapy after PCI. Patients informed about ADRs had lower incidences of self-reported ADRs and fewer concerns about prescribed pharmacotherapy.en_US
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleDischarge Information About Adverse Drug Reactions Indicates Lower Self-Reported Adverse Drug Reactions and Fewer Concerns in Patients After Percutaneous Coronary Interventionen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2023 The Author(s)en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.doi10.1016/j.hlc.2023.12.005
dc.identifier.cristin2229754
dc.source.journalHeart, Lung and Circulationen_US
dc.source.pagenumber350-361en_US
dc.identifier.citationHeart, Lung and Circulation. 2024, 33 (3), 350-361.en_US
dc.source.volume33en_US
dc.source.issue3en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Navngivelse 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Navngivelse 4.0 Internasjonal